FDA Approves Gemcitabine Intravesical System for Non-Muscle Invasive Bladder Cancer By Ogkologos - September 19, 2025 477 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the Cohort 2 of SunRISe-1 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Lurbinectedin Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian MOST POPULAR Extended Lymphadenectomy Does Not Improve DFS or OS Among Patients with... November 4, 2024 Regular Aspirin Use May Increase Older People’s Risk of Dying from... August 18, 2020 What if we count all that still remains? June 11, 2021 Neoadjuvant Pembrolizumab Associated with Limited Side Effects and High Clinical Activity... January 16, 2023 Load more HOT NEWS EMA Recommends Extension of Therapeutic Indications for Pembrolizumab PSMA PET-CT Accurately Detects Prostate Cancer Spread, Trial Shows Could proton beam therapy improve throat cancer treatment? Atezolizumab Plus Bevacizumab Approved to Treat Liver Cancer
